Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Early Pipeline Case Study

- PMLiVE

10 Top Tips to Optimise Your Virtual Conference

A virtual conference is a live digital event, built around an agenda to replicate an in-person event. In this blog, Digital Engagement Manager Laura Smith shares her 10 top tips...

IGNIFI

- PMLiVE

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

Trial halted early after crossing superiority boundary for the primary endpoint of invasive disease-free survival

EU flag

Pfizer/BioNTech and Moderna increase COVID-19 vaccine supplies to the EU

The EU now currently has access to 2.6 billion COVID-19 vaccine doses from a range of companies

- PMLiVE

The print edition of T40 2020 is available now!

The print edition contains exclusive results analysis and is easy to download

- PMLiVE

South African variant reduces antibody levels produced by Pifzer/BioNTech’s COVID-19 vaccine

Researchers noted it is 'unclear' what effect this reduction has on the vaccine's protection against the variant

- PMLiVE

akt health communications hires Heather Tarplee as senior account director

Prior to joining akt health, Tarplee worked at Freuds for five years

- PMLiVE

AI and accelerated computing ring in new era for healthcare

The AI trends set to dominate healthcare in 2021

- PMLiVE

HCA releases new PR media guide

The guide aims to help healthcare PR professionals understand how best to approach journalists

- PMLiVE

Novartis partners with Bill & Melinda Gates Foundation on ‘accessible’ sickle cell gene therapy

Project will aim to discover and develop a gene therapy for sickle cell disease

Pandemics for dummies

The mistakes are plentiful, but one stands out as most egregious

- PMLiVE

UK to launch world-first COVID-19 human challenge study in the ‘next few weeks’

Initial stage of the study will involve up to 90 healthy adult volunteers who will be exposed to COVID-19

- PMLiVE

GSK launches late-stage testing of RSV vaccine candidate in older adults

Vaccine candidate was found to be well-tolerated in a phase 1/2 trial

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links